

New Vaccines against Infectious Diseases: Research and Development Status

IVR, WHO, April 2005

Disease	Type of vaccine	Pharmaceutical company or Research group	Stage of development
Diarrheal Diseases			
Cholera	Killed O1 and O139 whole cell vaccine, oral	Nha-Trang, Vietnam	Phase II (Demonstration trial)
	Live attenuated, oral	Finlay Institute, Cuba	Phase II
	Live attenuated, oral	Avant Immunotherap / BioSidus	Phase II
	Live attenuated O139 strains	Univ Maryland	Phase I
	Conjugate vaccine (O Ag)	Pasteur Institute	Preclinical
	DNA	Putra Univ, Malaysia	Preclinical
ETEC	Inactivated 5-valent whole cell + rCTB, oral	Göteborg Univ, Sweden/ Active Biotech Res/ GSK	Phase III
	Live attenuated recombinant <i>Shigella</i> -ETEC fimbriae/LT, oral	Univ Maryland,	Preclinical
	Live attenuated recombinant <i>S. typhi</i> -ETEC, oral	Microscience	Preclinical
	Live attenuated strains (<i>omp R, aro C / omp C, omp F, aro C</i>), oral	Cambridge Biostability	Phase I
	Encapsulated colonization factors	Univ Maryland	Phase I
	Colonization factor + LT, transcutaneous	US Navy/ Iomai	Phase II
Rotavirus	Lamb-derived, live attenuated, oral	Lanzhou Inst Biol Prod, China	Used in China; controlled Phase III pending
	Live human neonatal strain, oral	GSK	Licensure
	Live bovine/human 4-valent reassortant, oral	Merck	Phase III completed; licensure pending
	Live bovine/human multivalent reassortant	NIAID	Phase II
	Live human neonatal strain, oral	Australia	Phase I
	Live attenuated, human neonatal strains, oral	India and PATH	Phase I
	RV VLPs	Various research groups	Preclinical
Shigellosis	Conjugate vaccine (PEA-PS)	NIH	Phase II in children
	Ribosomal preparation	IVI/WRAIR	Preclinical
	Inactivated whole cell, oral	Antex	Phase I
	Live attenuated <i>S. flexneri/sonnei</i> , oral	Lanzhou Inst Biol Prod, China	Phase III
	Live attenuated <i>S. flexneri/dysenteriae</i> , oral	Pasteur Institute /WRAIR / IVI	Phase I/II
	Live attenuated <i>S. flexneri/dysenteriae</i> /ETEC fimbriae,	Univ Maryland	Phase I
	Live attenuated <i>S. sonnei</i> (<i>Vir G</i>), oral	Univ Maryland	Phase I

Typhoid Fever	rPAE- Vi conjugate vaccine	NIH /Sanofi-Pasteur	Phase II/ III
	Ty800 live attenuated strain, oral	Avant Immunotherapeutics	Phase II
	Live attenuated CVD908-htrA and CVD 909, oral	Univ Maryland / Acambis; Berna	Phase II
	Live attenuated, oral	Microscience, Avant Immunotherapeutics	Phase II
Respiratory Diseases			
Influenza virus	Inactivated H5N1 reassortant virus vaccine	Sanofi-Pasteur; Chiron / NIH; Kitasato Inst, Japan	Phase I pending
	Inactivated H9N2	GSK	Phase I in preparation
	Live attenuated, cold-adapted strains, nasal	MedImmune	Phase III completed; licensure pending
	Live attenuated, nasal	Merck / Biodiem	Preclinical
	Live attenuated, cell-culture, nasal	Vector, Russia	Preclinical
	Live attenuated H9N2 and H5N1 strains, nasal	MedImmune	Preclinical
	Proteosome	ID Biomedical	Phase II
	Synthetic peptides, nasal	Yeda/ BiondVax, Israel	Phase I in preparation
	DNA	CDC; Vical; PowderJect	Phase I
	M2-HBc VLPs	Apovia / Univ Gent	Preclinical
	M2- <i>N. meningitidis</i> OMP and M2-KLH	Merck	Preclinical
Parainfluenza virus type 3 (PIV-3)	Live chimeric human / bovine PIV-3 reassortant	NIH; MedImmune	Phase I
	Live chimeric RSV / human PIV-3 / bovine PIV-3 reassortant, nasal	MedImmune	Preclinical
	Virosomes	Berna	Preclinical
Respiratory Syncytial Virus (RSV)	F protein subunit vaccines (PFP-2, PFP-3)	Wyeth	Phase II/III (children with CF); Phase II (pregnant mothers)
	F/G/ M proteins subunit vaccine	Sanofi-Pasteur	Phase II
	Live attenuated, cold-adapted <i>ts</i> strain, nasal	Wyeth/NIAID	Inactive
	Genetically engineered live attenuated vaccines	Wyeth/NIAID	Phase I
	Live chimeric RSV / human PIV-3 / bovine PIV-3, nasal	MedImmune	Preclinical
	Virosomes	Berna	Preclinical
Severe acute respiratory syndrome (SARS)	Whole inactivated virus	Sinovac, China;	Phase I
		Sanofi-Pasteur; Chiron; Baxter	Preclinical
	Live recombinant MVA-S protein	Rockefeller Univ	Preclinical
	Live recombinant Ad-S protein	Crucell	Preclinical
	S, S/M, or S/M/N subunit vaccines	Various academical institutions	Preclinical

Streptococcus pneumoniae (pneumococcal disease)	Conjugate 9-valent vaccine	Wyeth	End of Phase III
	Conjugate 11-valent vaccine	Sanofi-Pasteur;	Phase III
		GSK	Phase III completed (old formulation) / Phase II (improved)
	BVH3/11V fusion protein	ID BioMedical	Phase I completed
	PspA+PsaA	Sanofi-Pasteur	Phase I in adults
	Pneumolysin, PspA, adhesins, PiaA, PiuA, etc, subunit or DNA vaccines	Various academic institutions	Preclinical / Phase I
Tuberculosis	Modified BCGs :		
	-BCG30 (Ag85B)	UCLA	Phase I
	-BCG::RD1	Pasteur Institute	Preclinical
	-BCG: Δ ure C-Hly	Max Planck Institute	Prep for Phase I
	Live attenuated <i>M. tuber- culosis</i> Pho P mutant	Pasteur Institute/ Univ Zaragoza	Preclinical
	Live attenuated mc2 6020 / 6030 strains	Albert Einstein Coll Med, NY	Prep for Phase I
	Live, recombinant MVA-Ag85A	Oxford Univ	Phase I completed (BCG - primed volunteers)
	Live, recombinant Ad-Ag85A	Crucell / Aeras; GlobalTB Vaccine Foundation	Preclinical
	Mtb32 / Mtb39 fusion protein subunit vaccine	IDRI-Corixa / GSK	Phase I (BCG-primed volunteers)
	ESAT-6 / Ag85B fusion protein subunit vaccine	SSI	Prep for Phase I
	Mtb72F in AS02A subunit vaccine	GSK	Phase I
Multi-epitope peptide, mycolic acid, others	Intercell; others	Preclinical / Phase I	
Bacterial Diseases			
Anthrax	Protective antigen (PA) subunit vaccine	BioPort; Vaxgen	Phase I/II
	Live recombinant (MVA, <i>Salmonella</i> , <i>V. cholerae</i> ...)	Avant Immunotherapeutics;	Phase I
		others	Preclinical
Neisseria meningitidis (Groups A, C, Y, W135)	Group A PS conjugate	Serum Institute of India	Phase I
	Trivalent A, C, W135 PS	GSK	Phase II
	Tetavalent PS conjugate	Sanofi-Pasteur	Licensure
	Heptavalent DPT-HepB-Hib-MenA/C conjugate	GSK	Phase II
Neisseria meningitidis (Group B)	NZ Por A outer membrane vesicles	GSK	Phase II
		Chiron / Auckland Univ	Phase III/IV
	New membrane protein subunit vaccines	Chiron ; Microscience	Preclinical / Phase I
Plague	F1-V fusion protein subunit vaccine	DynPort Vaccine	Phase I
	Live recombinant <i>Salmonella</i> -F1-V	Avant Immunotherapeutics	Phase I

Group A <i>Streptococcus</i>	26-valent M protein N-terminal epitopes + conserved protein Spa	ID Biomedical	Phase II
	J14 moiety fusion peptide combined with 7-valent determinants on polymer backbone	Queensland Inst of Med Res, Australia	Ready to enter Phase I
	C-terminal half of M protein expressed as a fusion protein on surface of <i>Streptococcus gordonii</i>	Rockefeller Univ, New-York/ SIGA Technologies	Phase I
	Carbohydrate	Rockefeller Univ, New-York	Pre-clinical
	C5a peptidase	Minnesota Univ/Wyeth	Preclinical
	Stb1 subunit vaccine	Gesellschaft Biotechnologis- che Forschung, Germany	Preclinical
	Exotoxin A and C toxoids	Various groups	Preclinical
Group B <i>Streptococcus</i>	Conjugate Ia, Ib vaccine	NIH	Phase I
	Conjugate III vaccine	NIH ; Baxter	Phase I (pregnant women)
	New membrane protein subunit vaccines	Microscience; Intercell	Preclinical
Sexually Transmitted Diseases			
<i>Chlamydia trachomatis</i>	Membrane protein (OMP) subunit vaccine	Antex Biologics	Phase II
Herpes simplex type 2 (HSV-2)	gD2 subunit with AS04 adjuvant	GSK / NIH	Phase III (HSV seronegative women)
	Live attenuated ICP8 DISC virus vaccine	Xenova	Phase I/II
	Other live attenuated, replication - competent virus vaccines	Avant; AuRix	Phase I; Phase II
HIV / AIDS	Aldithriol- or NEM-inactivated whole virus	NCI	Preclinical
	Trimeric ΔV2 gp140 subunit vaccine;	Chiron	Phase I
	Disulfide -bound (SOS) trimeric gp140 subunit	Progenics	Preclinical
	Single chain CD4 mimic-gp120 subunit vaccine	Univ Maryland;	Preclinical
	Gp41 subunit vaccines	Vienna Univ; Mymetics; Merck; research groups	Preclinical
	Live, recombinant ALVAC-env/gag/pol/ nef + recombinant clade	Sanofi-Pasteur / WRAIR / VaxGen / Ministry of Health of Thailand	Phase III (Drug users)
	Live, recombinant MVA	Therion / IAVI; Aaron Diamon / IAVI	Phase I
	Live, recombinant non-replicative Ad5-gag /pol/ nef	Merck / NIAID	Phase II
		Vaccine Res Ctr (NIH)	Prep for Phase II with DNA prime
	Other live, non replicative Ad recombinants (Ad6, Ad35...)	IAVI/Crucell; Beth Israel Deaconess Med Ctr; Merck	Preclinical
	Live, recombinant attenuated measles virus vaccine	Pasteur Institute / GSK	Prep for Phase I
	Live recombinant fowlpox virus (clade E)	AVC (Australia)	Phase I (with DNA prime)
	DNA+ NYVAC (clade C)	Eurovac consortium (EU)	Phase I
	Other live recombinant vaccines (BCG, VEEV, AAV, <i>Salmonella</i> , VSV...)	NIH Japan; Alphavax; Targeted Genetics / IAVI ; Univ Maryland; Wyeth ...	Preclinical / Phase I
	DNA vaccines	Parexel; Wyeth / Univ Pennsylvania; Vical; Istituto Sup di Sanita	Phase I

	Gag-B. anthracis LF fusion protein subunit vaccine	Avant / WRAIR	Phase I
	Tat-Nef fusion protein +Env subunit vaccine	GSK	Prep for Phase I
	Polyepitopic polypeptides	Epimmune; Wyeth / Duke Univ; GAIA	Preclinical / Phase I
	Tat, Rev, Nef subunit vaccine	AVIP consortium (EU)	Phase I
	Gag, Pol, Nef lipopeptides	ANRS/NIAID	Phase II (suspended)
	CCR5 peptides ; CCR5-hsp70 fusion protein	Guy's Hospital, London ; Maryland Univ ; Various groups	Preclinical
Vector-borne Diseases			
Dengue Fever	Live attenuated, 4-valent vaccine	Sanofi-Pasteur / Mahidol	Phase II (pediatric)
	Live chimeric 4-valent Dengue/Yellow Fever vaccine	Acambis / Sanofi-Pasteur	Phase I (adults)
	Live attenuated (3'NCR), 4-valent vaccine	NIH	Phase I (as monovalent)
	Live attenuated DV-2 and DV-2/1, -2/3, -2/4 chimeric vaccines	CDC	Preclinical
	Tetravalent chimeric, F mutant	US FDA	Preclinical
	4-valent E-NS1 fusion protein subunit vaccine	Hawaii Biotech	Preclinical
	Other vaccines (DNA, recombinant MVA...)	NIH	Preclinical
Japanese Encephalitis	Inactivated Vero cell-grown SA14-14-2 strain	Intercell	Phase II/III (adults)
	Inactivated Vero cell-grown Beijing strain	Biken, Kaketsuken	Phase II/III
	Live, chimeric SA14 -14-2/Yellow Fever vaccine	Acambis	Phase II in adults
	Live MVA recombinant	Bavarian Nordic	Preclinical
West Nile virus	Live, chimeric WNV/ Dengue (DV-4) vaccine	NIH	Prep for Phase I
	Live, chimeric WNV/ Yellow Fever vaccine	Acambis	Phase I/II
	Inactivated virus vaccine	Crucell	Preclinical
	Glycoprotein subunit vaccine	Hawaii Biotech	Preclinical
	DNA vaccine, VLPs, others	Several institutions	Preclinical
Parasitic Diseases			
Hookworm Disease	ASP2 subunit vaccine	Human Hookworm Vaccine Initiative	Phase I
Leishmaniasis	Live attenuated / drug-sensitive strains	Various laboratories	Preclinical
	Killed promastigotes with BCG and alum	Razi Institute	Phase II
		BIOMM (Brazil)	Phase I/II
	LeIF/ LmSTI-1/ TSA fusion protein subunit vaccine	IDRI/Corixa	Phase I/Ib
	DNA, subunit vaccines (gp63, LeIF, PSA2, LACK antigen,...)	Various laboratories	Preclinical

Malaria	RTS,S: Hybrid <i>P. falciparum</i> CSP-HBsAg particles + AS02 adjuvant	GSK / WRAIR/MVI	Phase IIb
	Pre-erythrocyte stage		
	CSP C-ter peptide + Montanide ISA 720	Dictagen / Lausanne Univ	Phase Ib
	ICC-1132: Hybrid CSP multiepitope-HBc VLPs	Apovia/MVI	Phase II
	DNA vaccines (including MuStDO-5: CSP/LSA-1/ LSA-3/EXPI/TRAP)	US Navy/ Vical	Phase I
	Live recombinant FPV- or MVA-CSP + LSA-1 epitope	Oxford Univ/ Oxxon/MVI	Phase Ib
	Live recombinant MVA-multiepitope string + TRAP	Oxford Univ/Oxxon	Phase Ib
	Live recombinant Ad-CSP	Crucell/GSK/WRAIR/NIAID	Phase Ia
	Other live recombinant vaccines (MVA, cold-adapted influenza virus) CSP	Oxford Univ; NYU;	Preclinical
	LSA-3 (long peptides; lipopeptide;recombinant)	Pasteur Institute/WRAIR/ GSK	Phase Ia
	LSA-1, SALSA, other liver-stage antigens	Hawaii Biotech; Epimmune	Preclinical
	MSP-1 42 kD + AS02	GSK/WRAIR/MVI	Phase Ib/ II
	Blood-stage		
	AMA-1	MVDU; NIAID	Phase Ib
	PfCP 2.9: MSP-1-AMA-1 fusion protein (yeast) + Montanide ISA 720	Sec Military Med Univ Shanghai/Wanxing Pharmaceuticals/ WHO	Phase I
	Other MSP-1 derivatives (peptides, <i>Salmonella</i> or BCG)	NIAID; Hawaii Biotech; AECOM; Univ Maryland	Preclinical to Phase I
	MSP-3 long peptides	Pasteur Institute/ AMANET/EMVI	Phase Ib
	GLURP long peptide	EMVI/SSI	Phase I
	MSP-3-GLURP hybrid long peptide + Montanide ISA 720	EMVI/SSI	Phase I
	MSP-4, -5	Monash	Preclinical
	Combination B: MSP-1, -2, RESA + Montanide	Queensland Med Res Institute/WEHRI	Phase II
	SE36	Osaka Univ/Biken	Phase I
	Other blood-stage antigens (EBA-175,EBP2, MAEBL, RAP-2, EMP-1, DBL- α ..)	Various groups	Preclinical
	Sexual stage		
	PfS25 (yeast)	NIH	Phase I
	PvS25 and other sexual-stage antigens	NIH	Preclinical
	Schistosomiasis		
	<i>S. haematobium</i> 28kD GST subunit vaccine	Lille Pasteur Institute	Phase II
	<i>S. mansoni</i> paramyosin + TPI multiepitope	Bachem/USAID/SVDP	Preclinical
	<i>S. mansoni</i> Sm14	FioCruz	Preclinical
	Hepatitis and Cancers		
<i>Helicobacter pylori</i>	Whole cell vaccine with mutant LT adjuvant	Chiron; Antex	Phase I / II
Hepatitis B	HBc VLP+ cochleates, nasal	CIGB	Phase I
	HBV polyepitope vaccine	Innogenetics	Phase I
	HBsAg DNA vaccine	Pasteur Institute	Phase I
	DNA coding for T-cell epitopes	Genencor	Phase I

Hepatitis C	Recombinant E1/E2 + MF59 subunit vaccine	Chiron	Phase I
	Recombinant E1 glycoprotein subunit vaccine	Innogenetics	Phase II (therapy); Pre clinical for prevention
	HCCAg/E1/E2 VLPs	NIH	Preclinical
	HCCAg + ISCOMs	CSL, Australia /Chiron	Phase II
	Live recombinant MVA-NS3-NS4-NS5 antigens vaccine	Transgene/BioMerieux	Preclinical
	Multiepitope synthetic peptides in virosomes	Pevion	Preclinical
	Multigene recombinant Adenovirus	GenPhar	Preclinical
	Multiantigen DNA, peptides, others	Epimmune/Innogenetics, Merix..	Preclinical
Hepatitis E	56 kD ORF-2 protein VLPs (baculovirus)	GSK/WRAIR	Phase II/III
	DNA vaccine (ORF-2)	US Navy	Preclinical
	Live swine virus vaccine	NIH	Preclinical
Human papillomavirus	HPV-6,-11,-16,-18 L1 protein VLPs, yeast	Merck	Phase III completed; licensure pending
	HPV-16,-18 L1 protein VLPs, baculovirus	GSK	Phase III
	Live, recombinant <i>Salmonella</i> -HPV-16 L1 protein (VLP), oral	Univ Lausanne (Switzerland)	Preclinical
	HPV-16 L1 VLPs, tobacco; same, potato	Univ Cape Town; Xian Jiaotong Univ (China); Inst for Plant	Preclinical
	HPV-16 L1 VLPs / IL-2	Pochon Univ (S.Korea)	Preclinical
	Recombinant AAV-HPV16 L1 / GMCSF	Nat Defense Med Center, Taiwan	Preclinical
	HPV-16 L1 DNA vaccine	Swedish Institute for Infectious Diseases Control	Preclinical
	HPV-16 L1 DNA / RANTES	Pundang General Hospital (S. Korea)	Phase I
	HPV-16 L2 peptides, nasal	Tokyo Univ	Preclinical
Epstein-Barr Virus	Gp350 subunit vaccine	MedImmune/GSK/Henogen	Phase II
	EBNA-3A peptide	CSL, Australia	Phase I (discontinued)
	Live MVA –LMP2A recombinant	GSF, Germany	Preclinical
Enteroviruses			
Poliovirus	Whole inactivated Sabin strains (IPV)	JPRI, Japan;	Phase III/licensure
		Kunming Institute Med Biol, China; Panacea Biotech, India	Preclinical /Phase I
	Monovalent Sabin type 1 (OPV)	Sanofi-Pasteur; Panacea Biotech, India	Licensure